



REMARKS

RECEIVED

MAY 07 2002

TECH CENTER 1600/2900

Applicants claim priority to their co-pending application,

USSN 09/780,512, filed February 12, 2001.

Respectfully submitted,

William M. Blackstone  
Agent for Applicants  
Registration No. 29,772.

Attorney Docket No. 2001.682 US/PD  
Intervet Inc. Patent Department  
405 State Street  
P.O. Box 318  
Millsboro, DE 19966  
Tel: (302) 934-4317  
Fax: (302) 933-4013  
32MURPHY-CLAIM PRIORITY

COPY OF PAPERS  
ORIGINALLY FILED



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

MAY 07 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

This application is a continuation-in-part of USSN 09/780,512, filed February 12, 2001.

TECH CENTER 1600/2900

### **Field of the Invention**

The present invention relates to methods for improving the therapeutic response of human patients with major depression, particularly those carrying the gene for apolipoprotein E4.

### **Background of the Invention**

Psychiatric diseases generally provide a unique set of complications for clinicians, patients, and care givers. Major depression, for instance, is a major health problem and poses a tremendous financial burden on society due to lost self-support of individuals suffering from depression. Such individuals are often simply unable to function in everyday life situations, in part because of feelings of extreme hopelessness and worthlessness. There is also a serious risk of suicide among such individuals. The various forms of depression are defined and are separately diagnosed according to criteria given in handbooks for psychiatry, for example in the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) published by the American Psychiatric Association, Washington, D.C. (1994). The diagnostic criteria for major depression are well known to those skilled in the art, and comprise the criteria set forth, for example, at DSM-IV 296.2 and 296.3. Major depression, defined in more detail below, is also known as major depressive disorder and is estimated to affect between 5 to 10% of the human population.